# Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome

> **NCT01436227** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 32 (actual)

## Conditions studied

- Von Hippel-Lindau Syndrome

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Pazopanib Hydrochloride

## Key facts

- **NCT ID:** NCT01436227
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-17
- **Primary completion:** 2024-03-13
- **Final completion:** 2024-03-13
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01436227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01436227, "Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01436227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*